Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Amortizatization of Intangibles for 14 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortizatization of Intangibles fell 50.0% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 73.32% YoY), while the FY2025 annual figure was $4.0 million, down 69.23% from the prior year.
• Amortizatization of Intangibles improved to $1.0 million in Q1 2026 per RARE's latest filing, from $516000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $4.1 million in Q4 2023 and bottomed at -$1.9 million in Q1 2022.
• Historically, Amortizatization of Intangibles has averaged $1.7 million across 5 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2022 — Amortizatization of Intangibles tumbled 101.49% — and 2023, when it soared 376.68%.
• Ultragenyx Pharmaceutical's Amortizatization of Intangibles stood at $1.6 million in 2022, then surged by 148.85% to $4.1 million in 2023, then retreated by 22.5% to $3.2 million in 2024, then sank by 83.78% to $516000.0 in 2025, then soared by 93.8% to $1.0 million in 2026.
• Business Quant data shows RARE's Amortizatization of Intangibles at $1.0 million in Q1 2026, $516000.0 in Q4 2025, and $704000.0 in Q3 2025.